T1	Participants 181 186	human
T2	Participants 341 396	50 subjects receiving four doses of hepatitis B vaccine
T3	Participants 450 589	Twenty-three subjects were given a plasma-derived vaccine (Hevac B) and 27 received a recombinant HBsAg vaccine (yeast-derived; Engerix-B).
